Clinical trial · Interventional
CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies
Application of Humanized Anti-CD22 Antibody in CAR-T Therapy of B Cell Hematological Malignancies
NCT02794961CI-TRIAL-00022531unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
CD19 expression on B cell frequently lost after CD19-targeting CAR-T therapy. In present study, we construct a CD22-targeting chimeric antigen receptor to overcome this issue.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent or Refractory B Cell Malignancy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CD22 CAR-T | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- CD22 CAR-T
- description
- Enrolled patients will receive three escalating doses of autologous CAR-T.
- interventionNames
- Biological: CD22 CAR-T
Primary outcomes (1)
- measure
- Complete remission rate
- timeFrame
- 12 months
- description
- The B cells in peripheral blood of all enrolled patients will be monitored every week
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 4 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Greater than four years of age * Survival time\>12 weeks * B cell hematological malignancies by pathological examination * Chemotherapy failure or recurrent B cell malignancy * Creatinine\< 2.5mg/dl * Glutamic-pyruvic transaminase, glutamic oxalacetic transaminase\< 3 fold of normal level * Bilirubin\<2.0mg/dl * Karnofsky Performance Status\>50% at the time of screening * Adequate pulmonary, renal, hepatic, and cardiac function * Fail in autologous or allogenic haemopoietic stem cell transplantation * Free of leukocytes removal contraindications * Voluntarily join CAR-T clinical trial * Understand and sign written informed consent Exclusion Criteria: * Pregnant or nursing women * Active hepatitis B, active hepatitis C, or any human immunodeficiency virus (HIV) infection at the time of screening * Feasibility assessment proves that the efficiency of transduction of lymphocyte is below 10% or the lymphocyte cannot be propagated. * Abnormal vital signs * Highly allergic constitution or history of severe allergies, especially allergy to interleukin-2 * General infection or local severe infection, or other infection that is not controlled * Dysfunction in lung, heart, kidney and brain * Severe autoimmune diseases * Other symptoms that are not applicable for CAR-T
References
Publications (1)
- RESULTHaso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, FitzGerald DJ, Barrett DM, Wayne AS, Mackall CL, Orentas RJ. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013 Feb 14;121(7):1165-74. doi: 10.1182/blood-2012-06-438002. Epub 2012 Dec 14. PMID 23243285